1. The PTP1B mutant PTP1B∆2–4 is a positive regulator of the JAK/STAT signalling pathway in Hodgkin lymphoma
    Malena Zahn et al, 2021, Carcinogenesis CrossRef
  2. Epigenetic Regulation of Multidrug Resistance Protein 1 and Breast Cancer Resistance Protein Transporters by Histone Deacetylase Inhibition
    Dahea You et al, 2020, Drug Metabolism and Disposition CrossRef
  3. Histone-acetyl epigenome regulates TGF-β pathway-associated chemoresistance in colorectal cancer
    Xianglong Tian et al, 2025, Translational Oncology CrossRef
  4. Mechanisms of resistance to chemotherapy in non-small cell lung cancer
    Hye-Young Min et al, 2021, Archives of Pharmacal Research CrossRef
  5. HDAC2 overexpression is a poor prognostic factor of breast cancer patients with increased multidrug resistance-associated protein expression who received anthracyclines therapy
    Haishan Zhao et al, 2016, Japanese Journal of Clinical Oncology CrossRef
  6. Formoxanthone C, isolated from Cratoxylum formosum ssp. pruniflorum, reverses anticancer drug resistance by inducing both apoptosis and autophagy in human A549 lung cancer cells
    Chutima Kaewpiboon et al, 2018, Bioorganic & Medicinal Chemistry Letters CrossRef
  7. Functional role of miR-10b in tamoxifen resistance of ER-positive breast cancer cells through down-regulation of HDAC4
    Aamir Ahmad et al, 2015, BMC Cancer CrossRef
  8. Histone deacetylase HDAC4 promotes the proliferation and invasion of glioma cells
    Jun-Yan Cai et al, 2018, International Journal of Oncology CrossRef
  9. Genome-wide identification of methylated CpG sites in nongenital cutaneous warts
    Laith N. AL-Eitan et al, 2020, BMC Medical Genomics CrossRef
  10. HDAC2 was involved in placental P-glycoprotein regulation both in vitro and vivo
    Hongyu Duan et al, 2017, Placenta CrossRef
  11. Understanding Cancer’s Defense against Topoisomerase-Active Drugs: A Comprehensive Review
    Nilesh Kumar Sharma et al, 2024, Cancers CrossRef
  12. In silico Design of Novel Histone Deacetylase 4 Inhibitors: Design Guidelines for Improved Binding Affinity
    Shana V. Stoddard et al, 2019, International Journal of Molecular Sciences CrossRef
  13. Andrographolide targets EGFR to impede epithelial–mesenchymal transition in human breast cancer cells
    Chutima Kaewpiboon et al, 2024, Journal of Pharmaceutical and Biomedical Analysis CrossRef
  14. Identifying the role of Wilms tumor 1 associated protein in cancer prediction using integrative genomic analyses
    Li-Sheng Wu et al, 2016, Molecular Medicine Reports CrossRef
  15. MiR‐520b restrains cell growth by targeting HDAC4 in lung cancer
    Ke Jin et al, 2018, Thoracic Cancer CrossRef
  16. Caged-xanthone from Cratoxylum formosum ssp. pruniflorum inhibits malignant cancer phenotypes in multidrug-resistant human A549 lung cancer cells through down-regulation of NF-κB
    Chutima Kaewpiboon et al, 2019, Bioorganic & Medicinal Chemistry CrossRef
  17. Formoxanthone C Inhibits Malignant Tumor Phenotypes of Human A549 Multidrug Resistant-cancer Cells through Signal Transducer and Activator of Transcription 1-Histone Deacetylase 4 Signaling
    Chutima Kaewpiboon et al, 2022, Journal of Cancer Prevention CrossRef
  18. The multifaceted influence of histone deacetylases on DNA damage signalling and DNA repair
    Wynand Paul Roos et al, 2016, Nucleic Acids Research CrossRef
  19. The assessment of correlation and prognosis among 18F-FDG uptake parameters, Glut1, pStat1 and pStat3 in surgically resected non-small cell lung cancer patients
    Hayato Kaida et al, 2018, Oncotarget CrossRef
  20. Yeast β-glucan Increases Etoposide Sensitivity in Lung Cancer Cell Line A549 by Suppressing Nuclear Factor Erythroid 2-Related Factor 2 via the Noncanonical Nuclear Factor Kappa B Pathway
    Ferbian Milas Siswanto et al, 2022, Molecular Pharmacology CrossRef
  21. Roles of Histone Deacetylase 4 in the Inflammatory and Metabolic Processes
    Hyunju Kang et al, 2024, Diabetes & Metabolism Journal CrossRef
  22. Targeting HDAC with a novel inhibitor effectively reverses paclitaxel resistance in non-small cell lung cancer via multiple mechanisms
    L Wang et al, 2016, Cell Death & Disease CrossRef
  23. The good and the bad faces of STAT1 in solid tumours
    Katrin Meissl et al, 2017, Cytokine CrossRef
  24. Combination Therapy Using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy
    Mohammed G. Ghonime et al, 2018, Cancer Immunology Research CrossRef
  25. JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression
    Katie L. Owen et al, 2019, Cancers CrossRef
  26. A large scale proteome analysis of the gefitinib primary resistance overcome by KDAC inhibition in KRAS mutated adenocarcinoma cells overexpressing amphiregulin
    Sylvia G. Lehmann et al, 2019, Journal of Proteomics CrossRef

  27. Targeting IFN/STAT1 Pathway as a Promising Strategy to Overcome Radioresistance


    Shuya Liu et al, 2020, OncoTargets and Therapy CrossRef
  28. MiR-192 and miR-662 enhance chemoresistance and invasiveness of squamous cell lung carcinoma
    Martyna Filipska et al, 2018, Lung Cancer CrossRef